BAY2927088_formulation B_1 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

Bayer1

Indications

EGFR Mutation1
HER2 Mutation1
Advanced Non-Small Cell Lung Cancer1
Lung Cancer1
Cancer1

Gilbert, Arizona1 trial

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.